Dyshidrosiform Bullous Pemphigoid: Case Reports and Review.

blister bullous corticosteroid dyshidrosiform dyshidrosis dyshidrotic elderly pemphigoid pompholyx vesicle

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
11 Jan 2020
Historique:
entrez: 18 2 2020
pubmed: 18 2 2020
medline: 18 2 2020
Statut: epublish

Résumé

Bullous pemphigoid is an autoimmune blistering disorder that typically presents in elderly patients as pruritic tense subepidermal blisters on the lower trunk, axilla, and groin. It is caused by circulating and tissue-bound autoantibodies directed against bullous pemphigoid antigen 1 or bullous pemphigoid antigen 2 or both. Dyshidrosiform bullous pemphigoid is a rare variant of bullous pemphigoid, and it usually presents as itchy, potentially hemorrhagic, or purpuric blisters on the palms and/or soles of elderly individuals; subsequently, typical bullous lesions of bullous pemphigoid appear on other body sites. In our study, we report the features of two men with dyshidrosiform bullous pemphigoid and review the characteristics of individuals with this rare subtype of bullous pemphigoid. Including the men whose condition is described in this paper, at least 72 patients with dyshidrosiform bullous pemphigoid have been reported so far. However, complete features of the condition have not been described for all of the individuals. Based on the cases reported so far, the condition was slightly more common in women and the onset of the disease, for most of the patients, occurred between the ages of 61 and 94 years. The patients usually presented with blisters on both their palms and soles (66%) or just their soles (31%); 77% of the patients had progression of bullous pemphigoid to other areas of their body. Whether hemorrhagic blisters or purpuric lesions are associated with dyshidrosiform bullous pemphigoid remains to be determined; these features were present in 91% of the 22 patients who were described in the case reports yet were only observed in 5% of the individuals from a single larger series of 20 patients. The mainstay of therapy for dyshidrosiform bullous pemphigoid is systemic corticosteroids, with or without topical corticosteroids, and/or systemic dapsone or immunosuppressants; nearly all of the patients showed improvement after the treatment was initiated. Similar to individuals with bullous pemphigoid, at least nine of the dyshidrosiform bullous pemphigoid patients, including both patients in this report, had either a neurologic condition (seven patients) or both a neurologic condition and a psychiatric disorder (two patients). Usually, an autoimmune bullous disease, particularly dyshidrosiform bullous pemphigoid, is not initially considered in patients who present with blisters restricted to the palms and/or soles. Indeed, the lesion morphology of dyshidrosiform bullous pemphigoid mimics several other conditions that are characterized by blisters on the hands and feet, such as allergic and irritant contact dermatitis, chronic bullous disease of childhood, cutaneous T-cell lymphoma, dermatophyte infection, dyshidrosis or pompholyx, epidermolysis bullosa acquisita, erythema multiforme, herpes gestationis, lichen planus, linear IgA disease, scabies, and systemic contact dermatitis. In conclusion, the possibility of dyshidrosiform bullous pemphigoid should be considered in elderly individuals who present with the new onset of palmar and/or plantar blisters that are either recurrent or recalcitrant to therapy or would subsequently also appear on other areas of the body.

Identifiants

pubmed: 32064205
doi: 10.7759/cureus.6630
pmc: PMC7008730
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e6630

Informations de copyright

Copyright © 2020, Cohen et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Arch Dermatol. 1979 Mar;115(3):320-1
pubmed: 373634
J Dermatol. 2006 May;33(5):375-6
pubmed: 16700674
J Cutan Med Surg. 2018 Nov/Dec;22(6):614-617
pubmed: 29502439
Am J Clin Dermatol. 2017 Aug;18(4):513-528
pubmed: 28247089
Acta Derm Venereol. 2004;84(3):253-4
pubmed: 15202856
Acta Derm Venereol. 1981;61(5):417-21
pubmed: 6172930
Hautarzt. 1993 Dec;44(12):785-8
pubmed: 8113043
Int J Dermatol. 1986 Jan-Feb;25(1):17-27
pubmed: 3512459
J Dermatol. 2003 Jul;30(7):525-9
pubmed: 12928541
Clin Exp Dermatol. 1986 Jul;11(4):409-12
pubmed: 2948742
Int J Dermatol. 2005 Apr;44(4):312-4
pubmed: 15811084
Front Immunol. 2019 Jul 02;10:1506
pubmed: 31312206
Ann Dermatol Venereol. 1995;122(3):81-3
pubmed: 7486727
J Eur Acad Dermatol Venereol. 2003 May;17(3):370
pubmed: 12702100
Hautarzt. 2002 Nov;53(11):739-43
pubmed: 12402137
Clin Exp Dermatol. 1988 Sep;13(5):342-3
pubmed: 2978469
Clin Exp Dermatol. 1988 Mar;13(2):85-6
pubmed: 2975200
An Bras Dermatol. 2019 Mar-Apr;94(2):133-146
pubmed: 31090818
Clin Exp Dermatol. 1996 Jan;21(1):20-2
pubmed: 8689763

Auteurs

Philip R Cohen (PR)

Dermatology, San Diego Family Dermatology, San Diego, USA.

Classifications MeSH